Importantly, FGF2-targeted therapies, such as anti-FGF2 antibodies, significantly hampered the secretion of IL-6 and anti-IL-6 antibodies inhibited the secretion of FGF2 by MM cells [95]. Here, FGF2 is linked to Miyoshi myopathy.